Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties by Matthew, Lawrence et al.
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
Platelets
                          
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa33740
_____________________________________________________________
 
Paper:
Knowles, R., Lawrence, M., Ferreira, P., Hayman, M., D’Silva, L., Stanford, S., Sabra, A., Tucker, A., Hawkins, K.,  et.
al. (2017).  Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties.
Platelets, 1-9.
http://dx.doi.org/10.1080/09537104.2017.1306039
 
 
 
 
 
 
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/ 
 For Peer Review Only
 
 
 
 
 
 
Platelet reactivity influences clot structure as assessed by 
fractal analysis of viscoelastic properties 
 
 
Journal: Platelets 
Manuscript ID CPLA-2016-0332.R2 
Manuscript Type: Original Article 
Date Submitted by the Author: 01-Mar-2017 
Complete List of Authors: Knowles, Rebecca; Queen Mary University of London,  
Lawrence, Matthew; School of Medicine Swansea University, ; NISCHR 
Haemostasis Biomedical Research Unit, Morriston Hospital,  
Ferreira, Plinio; William Harvey Research Institute 
Hayman, Melissa; William Harvey Research Institute 
D'Silva, Lindsay; School of Medicine Swansea University, ; NISCHR 
Haemostasis Biomedical Research Unit, Morriston Hospital,  
Stanford, Sophia; Swansea University 
Sabra, Ahmed; Abertawe Bro Morgannwg University Health Board 
Tucker, Arthur; William Harvey Research Institute 
Hawkins, Karl; Swansea University 
Williams, Phylip; Swansea University 
Warner, Timothy; Barts and the London School of Medicine and Dentistry,  
Evans, Phillip; Haemostasis Biomedical Research Unit, Swansea University,  
Keywords: 
Blood coagulation, Blood platelets, Fibrin, Platelet aggregation inhibitors, 
Thrombosis 
  
 
 
URL: http://mc.manuscriptcentral.com/cpla E-mail: P.Harrison.1@bham.ac.uk
Platelets
For Peer Review Only
1 
 
Platelet reactivity influences clot structure as assessed by fractal analysis of 
viscoelastic properties 
Rebecca B. Knowles*, Matthew J. Lawrence†,‡, Plinio M. Ferreira*, Melissa A. 
Hayman*, Lindsay A. D’Silva†,‡, Sophie N. Stanford†,‡, Ahmed Sabra†,‡, Arthur T. 
Tucker*, Karl M. Hawkins†,‡, Phylip R. Williams§, Timothy D. Warner*,1, Phillip A. 
Evans†,‡,1 
*William Harvey Research Institute, Barts & the London School of Medicine & 
Dentistry, Queen Mary University of London, London, United Kingdom. † Medical 
School, Swansea University, Swansea, UK. ‡NISCHR Haemostasis Biomedical 
Research Unit, ABMU Health Board, Swansea, UK. §College of Engineering, 
Swansea University, Swansea, UK. 1Both authors claim dual ownership as 
corresponding authors 
Corresponding Author: Professor Phillip Adrian Evans, Professor of Emergency 
Medicine and Haemostasis, NISCHR Haemostasis Biomedical Research Unit, 
Morriston Hospital, ABMU Health Board, Swansea, SA6 6NL, United Kingdom, Tel: 
+44 1792 70 3418 Fax: +44 1792 53 2446 Email: phillip.evans2@wales.nhs.uk 
Short title: Platelets and clot structure 
Key words: Blood coagulation, Blood platelets, Fibrin, Platelet aggregation 
inhibitors, Thrombosis 
Word count for text: 4570 words 
Word count for abstract: 276 words 
Number of figures and tables: 7 (+7 supplemental) 
Number of references: 50 
  
Page 1 of 38
URL: http://mc.manuscriptcentral.com/cpla E-mail: P.Harrison.1@bham.ac.uk
Platelets
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
2 
 
Abstract 
Despite the interwoven nature of platelet activation and the coagulation system in 
thrombosis few studies relate both analysis of protein and cellular parts of 
coagulation in the same population. In the present study, we use matched ex vivo 
samples to determine the influences of standard anti-platelet therapies on platelet 
function and use advanced rheological analyses to assess clot formation. Healthy 
volunteers were recruited following fully informed consent then treated for 7 days 
with single anti-platelet therapy of aspirin (75 mg) or prasugrel (10 mg) or with dual 
anti-platelet therapy (DAPT) using aspirin (75 mg) plus prasugrel (10 mg) or aspirin 
(75mg) plus ticagrelor (90mg).  Blood samples were taken at day 0 before treatment 
and at day 7 following treatment. We found that aspirin plus prasugrel or aspirin plus 
ticagrelor inhibited platelet responses to multiple agonists and reduced P-selectin 
expression. Significant platelet inhibition was coupled with a reduction in fractal 
dimension corresponding to reductions in mean relative mass both for aspirin plus 
prasugrel (-35±16% change, p=0.04) and for aspirin plus ticagrelor (-45±14% 
change, p=0.04). Aspirin alone had no effect upon measures of clot structure 
whereas prasugrel reduced fractal dimension and mean relative mass. These data 
demonstrate that platelets are important determinants of clot structure as assessed 
by fractal dimension (df) and that effective platelet inhibition is associated with a 
weaker, more permeable fibrin network.  This indicates a strong association between 
the therapeutic benefits of anti-platelet therapies and their abilities to reduce 
thrombus density that may be useful in individual patients to determine the functional 
relationship between platelet reactivity, eventual clot quality and clinical outcome. df 
could represent a novel risk stratification biomarker useful in individualising anti-
platelet therapies. 
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Introduction 
Development of the platelet-rich fibrin clot at sites of atherosclerotic plaque rupture is 
central to atherothrombotic disease [1].  Platelets are critical to the processes of 
atherothrombosis, driving thrombus formation through a cascade of complex 
intracellular signalling pathways and powerful positive feedback loops [2, 3]. 
Platelets also have a central role in cell-based regulation of the coagulation system 
[4-6]. Because of the fundamental involvement of platelets in atherothrombosis, 
antiplatelet drugs that target amplifying secondary platelet agonists are the standard 
of care for the prevention of thrombotic events in patients with cardiovascular 
disease [7, 8]. Aspirin irreversibly blocks the cyclooxygenase enzyme (COX) to 
inhibit thromboxane A2 (TXA2) production [9] whilst P2Y12 receptor antagonists such 
as clopidogrel and prasugrel block the effects of pro-aggregatory ADP [10]. Together 
these agents constitute dual antiplatelet therapy (DAPT). Despite this approach 
adverse thrombotic events still occur and high on-treatment platelet reactivity to ADP 
[11] and aspirin resistance [12] are associated with adverse clinical outcome. This 
has led to questioning of the current ‘one size fits all approach’ to DAPT and the 
development of the concept of tailored antithrombotic therapies. However, to date 
attempts to use platelet testing to personalise therapy have repeatedly failed to 
provide any improvement in clinical outcome in randomised clinical trials [13-15]. 
 
Coagulation pathway changes also play central roles in clot propagation, a process 
that is affected by many factors both genetic and environmental [16]. Configuration 
of the fibrin network is a vital determinant of clot stability and susceptibility to 
fibrinolysis [15, 17] with clot permeability being the rate limiting factor for the activity 
of plasmin, the fibrin network degradation enzyme. Clots composed of compact thin 
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fibres are associated with thrombotic events [18, 19] and clot structure appears 
unfavourably altered in coronary artery disease and other conditions associated with 
thrombosis [20-23] and is also associated with adverse events following 
percutaneous coronary intervention. It has therefore, been suggested that there is a 
definitive diagnostic potential in characterising clot structure and modulation of clot 
architecture as a possible treatment for thrombosis [24]. However, many techniques 
that assess the mechanics and quality of clot architecture rely on processed samples 
using altered blood in remote laboratories, limiting their clinical use.  
 
Viscoelastic properties have been shown to be the most sensitive measures of fibrin 
polymerisation and blood clot structure [25] and recent advances in our 
understanding of the viscoelastic changes taking place in coagulation have resulted 
in the development of new methods for the analysis of clot characteristics. These 
properties can be quantified using small amplitude oscillatory shear rheometry to 
measure the gel point (GP), a multi-faceted biomarker that defines the transition 
between viscoelastic fluid and viscoelastic solid states during gelation. The technique 
uses unadulterated whole blood and is measured immediately at the bedside during 
real-time clot formation, providing a rapid assessment of coagulation that can be 
more readily performed than current methods. In coagulating blood the GP marks 
the establishment of the incipient clot and provides three important characteristics of 
the clot, all calculated from one measurement: time taken to reach GP or gel time 
(TGP); clot elasticity/strength (G’GP) and the fractal dimension (df) of the incipient clot 
[26]. Fractal dimension is a common technique used in biology to characterize 
nonlinear growth in branching network structures [27].  Importantly the measurement 
of df at the GP provides a quantitative assessment of clot structure where in studies 
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using viscoelastic and imaging data it has been shown to act as the template for 
mature clot development [26][27]. Reduced df is associated with more permeable, 
less branched and mechanically weaker clots and a raised df corresponds to a tightly 
packed, highly branched clot that is less permeable and stronger. Several studies 
have highlighted the potential of df as a biomarker in determining the effects of 
disease and therapeutic intervention on clot quality [26][28-31]. However, we are yet 
to establish the effects of individual anti-platelet therapies on clot structure and 
whether these are quantifiable by our novel GP technique. 
 
Here, we therefore apply the GP technique together with standard measures of 
platelet reactivity in blood samples taken from healthy volunteers treated with 
standard anti-platelet therapies, to investigate the complex interplay of platelets in 
the formation of clot structure and further validate the role of GP as a possible 
clinical biomarker. Such an approach may well provide a globally representative 
marker of haemostasis and thrombosis that could permit a more personalised 
approach to antiplatelet therapy.  
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Materials and Methods 
Study participants 
16 healthy, male volunteers (aged 18-40 years) participated in an initial single anti-
platelet therapy study. Health status was determined though medical history and 
physical examination, including blood pressure, pulse rate, blood chemistry and 
urinalysis. Volunteers with normal clinical profiles were included in the study. 
Subsequently, a further 20 healthy volunteers were recruited in an identical manner 
for a follow-up dual anti-platelet therapy study. Both studies were approved by St 
Thomas’s Hospital Research Ethics Committee (Ref. 07/Q0702/24) and all 
volunteers gave written consent before entering the study.  
 
Study protocol 
All healthy volunteers abstained from aspirin, non-steroidal anti-inflammatory drugs 
(NSAIDs) and any other anti-platelet therapy for 14 days before commencing the 
studies. Two groups of 8 volunteers received monotherapy aspirin (75 mg; Nu-Seals 
Cardio 75, Alliance Pharmaceuticals Ltd, Chippenham, UK) or prasugrel (10 mg; 
Effient®, Eli Lilly, RA Houten, The Netherlands) for 7 days. Subsequently, two 
groups of 10 volunteers received dual anti-platelet therapy (DAPT) with either aspirin 
(75 mg) plus prasugrel (10 mg) or aspirin (75mg) plus ticagrelor (90mg; Brilique®, 
AstraZeneca, Södertälje, Sweden), for 7 days. Compliance was assessed by 
interview. Blood samples were collected prior to and following drug treatment in both 
studies. 
 
Blood collection 
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In all cases blood was obtained from an antecubital vein via a 19-gauge butterfly 
needle and all experiments were completed within 2 hours of blood collection. 
 
Laboratory markers 
Blood was taken for full blood count (FBC) analysis, including platelet count and 
haemoglobin into 4ml EDTA vacutainers and into 4.5ml citrate vacutainers (BD 
Biosciences, UK) for routine coagulation studies, including prothrombin time (PT), 
activated partial thromboplastin time (APTT), APTTr, INR and fibrinogen.  
Measurements were made by use of automated analysers, Sysmex XN-2000 and 
Sysmex CS-2100i (Lincolnshire, USA). 
 
Platelet function 
Blood for platelet aggregation was collected into tri-sodium citrate (0.32 % final; 
Sigma, Poole, Dorset, UK). Platelet-rich plasma (PRP) was obtained by 
centrifugation at 175 x g for 15 min at 25˚C. Platelet-poor plasma (PPP) was 
obtained by centrifugation of PRP at 15 000 x g for 2 min.  
 
Light Transmission Aggregometry (LTA) 
Baseline aggregation of PRP to arachidonic acid (AA, final concentration, 1 mM; 
Sigma), adenosine diphosphate (ADP, 5 and 20 µM; Labmedics, Salford, 
Manchester, UK), Horm collagen (0.4, 4 and 10 µg/mL; Nycomed, Linz, Austria), 
U46619 (10 µM; Cayman Chemical Company, Ann Arbor, MI, USA) and TRAP-6 
amide specific for PAR1 (TRAP-6, 25 µM; SFLLRN, Bachem, Bubendorf, 
Switzerland) was measured in a Bio/Data PAP-8E turbidimetric aggregometer (5 
minutes, 1200 rpm, 37°C; Alpha Laboratories, Eastleigh, UK) before and following 
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treatment.  
 
ADP+ATP Secretion 
ADP+ATP secretion of PRP was evaluated by luminescence in the presence of 
Chrono-Lume reagent (0.2 µM luciferin/luciferase; Chronolog) after stimulation with 
collagen (4 µg/mL) in an optical lumi-aggregometer (560 CA; Chronolog, Havertown, 
PA, USA) before commencing and on completion of therapy. 
 
P-Selectin Expression and GPIIb/IIIa Activation 
PRP was activated with TRAP-6 (25 µM) under slow stirring conditions (300 rpm, 37 
°C). After 2 minutes, the reaction was stopped by dilution in ice cold 0.9% saline. 
Platelets were immediately stained with anti–CD61-allophycocyanin (CD61-APC; 
eBioscience, Hatfield, UK), PAC-1-FITC (BD Bioscience, Oxford, UK), and anti–p-
selectin-PE (eBioscience) for 15 min at 4°C and then fixed in 2% (vol/vol) formalin 
(Sigma). PAC-1-FITC and anti–p-selectin-PE immunoreactivity was measured by 
flow cytometry using a FACSCalibur instrument (Becton Dickenson, Oxford, UK). 
 
Rheometry 
9ml aliquots of blood collected into Vacuette vacutainers (Greiner Bio-One, Austria) 
without anti-coagulant were transferred directly and immediately (< 60 seconds) after 
sampling to a double-gap concentric cylinder geometry of a TA instruments 
Discovery HR-2 controlled stress rheometer (New Castle, DE, USA). All work was 
conducted at 37(±0.1) °C and all measurements were made on aliquots of the same 
sample by use of similar measuring geometries with identical measuring surfaces 
and surface preparation procedures. The viscoelastic properties of incipient clots 
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were determined by detecting the Gel Point (GP) of samples of whole unadulterated 
blood using small amplitude oscillatory shear rheometry [32]. From which the values 
of TGP and df were measured. The GP technique used in this study has been 
previously validated for use with blood elsewhere in several other studies [26,29-32]. 
The value of df measured at the GP can be equated to the mass of the clot. In 
previous studies we have shown there is an exponential relationship between df and 
clot mass [33]. In the present study we recreated this relationship and used it to 
calculate the relative mass (RM) for each of the df values. In this approach the mass 
of a random fractal aggregate (RFA) varies as a function of fractal dimension, via the 
following scaling law ~, where  are the characteristic length scales of the 
RFA (we assume the fibrin structure to be fractal over the range (100nm - 60m) 
commensurate with light scattering experiments conducted by Ferri et al. [34].  
 
Scanning Electron Microscopy 
For scanning electron microscopy (SEM) samples at each time point were allowed to 
clot at 37°C for a minimum of 15 mins.  Samples were then washed three times with 
2 cocadylate buffer pH 7.2 for the removal of excess salt and fixed for a minimum of 
4 h in 2% glutaraldehyde solution.  The clots were then rinsed with cocadylate buffer 
and dehydrated in a series of ethanol concentrations from 30 to 100%.  The clots 
were then critical point dried with hexamethyldisilazane for 45 min and placed in a 
fume hood for 24 hrs.  Finally, the clots were mounted to 0.5” SEM stubs (Agar 
Scientific, UK) and sputter coated with gold palladium. All samples were investigated 
with a Hitachi S4800 scanning electron microscope (Hitachi, High-Technologies 
Corporation, Tokoyo, Japan) [35]. All images were acquired with a constant 
resolution of 5.0kV (accelerating voltage) and a semi-in-lens achieving ultra-high 
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resolution. A combination of upper and lower signal detectors were used to collect 
the electron signals. 
 
Statistics and Data Analysis 
Clot fractal dimension (df), relative mass (RM) and haematological and haemostatic 
data were analysed by Wilcoxon signed rank tests. Pearson correlation coefficients 
were calculated for df and TGP versus haematological and haemostatic parameters. 
Flow cytometry data was analysed using FlowJo v8.7 (Treestar, Ashland, USA) 
where the “single platelet” population was gated based on forward scatter and CD61-
APC immunoreactivity (FL-4 mean fluorescence intensity). Unless otherwise stated, 
platelet response data in LTA, lumi-aggregometry and flow cytometry was analysed 
by paired t-test, using Prism v6.0e (Graphpad software, USA). Statistical significance 
was determined as described above and data sets considered different if p<0.05.  
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Results 
Effects of aspirin (75 mg) therapy on platelet reactivity and fractal analysis of 
incipient clots 
In individuals taking aspirin, standard LTA responses to AA (1 mM) and collagen (0.4 
µg/ml) were strongly inhibited. Responses to ADP (5 µM) were also significantly 
reduced whilst those to ADP (20 µM), collagen (4 µg/ml), U46619 (10 µM) and 
TRAP-6 (25 µM) were unaffected (Figure 1A).  Similarly, aspirin therapy did not 
affect dense granule secretion induced by collagen (4 µg/ml) as measured by ATP 
release (Figure 1B), or TRAP-6 (25 µM) induced PAC-1 binding (Figure 1C) and p-
selectin expression (Figure 1D). Haematological parameters, selected haemostatic 
parameters and gel time were not altered (Supplementary, Table 2 & 6). Aspirin 
treatment also produced no significant changes in the value of df (1.71±0.01 to 
1.69±0.01, p=0.41) (Supplementary, Table 7)  or the relative mass (-8±19% change, 
p=0.47) of incipient clots. 
 
Effects of prasugrel (10 mg) monotherapy on platelet reactivity and fractal analysis of 
incipient clots 
Following prasugrel therapy aggregatory responses to AA (1 mM), collagen (0.4 and 
4 µg/ml), ADP (5 and 20 µM), as well as U46619 (10 µM) were all significantly 
reduced. TRAP-6 (25 µM)-induced aggregation however, was unaffected (Figure 
2A). ATP release induced by collagen (4 µg/ml) was significantly decreased (Figure 
2B), as was TRAP-6 (25 µM) induced PAC-1 (Figure 2C) and p-selectin expression 
(Figure 2D). Haematological parameters, and selected haemostatic parameters and 
gel time were not altered (Supplementary, Table 3 & 6). There were notable 
reductions in df (1.72±0.02 to 1.67±0.01, p =0.03) (Supplementary, Table 7) and 
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mean relative mass values (-40±11% change, p=0.03) for incipient clots formed 
following prasugrel therapy. 
 
Characterisation of dual anti-platelet therapy with aspirin (75mg) plus prasugrel (10 
mg) on platelet reactivity and fractal analysis of incipient clots 
Platelet aggregation induced by AA (1mM), collagen (0.4 µg/ml) and ADP (5 µM and 
20 µM) in LTA were abolished in individuals taking prasugrel plus aspirin whilst 
responses to collagen (4 µg/ml), U46619 (10 µM) and TRAP-6 (25 µM) were also all 
significantly inhibited (Figure 3A). TRAP-6 (25 µM) induced p-selectin expression 
was also decreased (Figure 3B). There was a significant reduction in the df value 
(1.73±0.02 to 1.68±0.02, p=0.03) (Supplementary, Table 7) for incipient clots and a 
resulting decrease in mean relative mass (-35±16% change, p=0.04). 
Haematological parameters, and selected haemostatic parameters and gel time 
were not altered (Supplementary, Table 4 & 6). 
 
Characterisation of dual anti-platelet therapy with aspirin (75mg) plus ticagrelor (90 
mg) on platelet reactivity and fractal analysis of incipient clots 
Following dual anti-platelet therapy with aspirin plus ticagrelor platelet responses 
followed a similar pattern to those in individuals taking aspirin plus prasugrel; 
aggregations induced by AA (1mM), collagen (0.4 µg/ml) and ADP (5 µM and 20 µM) 
were powerfully inhibited and those to collagen (4 µg/ml), U46619 (10 µM) and 
TRAP-6 (25 µM) were significantly reduced (Figure 4A). These reductions were 
associated with a reduction in p-selectin expression (p<0.05; Figure 4B) induced by 
TRAP-6 (25 µM). Similarly, there were significant decreases in df for incipient clots 
formed (1.72±0.03 to 1.62±0.02, p=0.04) (Supplementary, Table 7) and marked 
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reductions in mean mass values (-45±14% change, p=0.04). Haematological 
parameters, and selected haemostatic parameters and gel time were not altered 
(Supplementary, Table 5 & 6) 
 
Clot structure analysis by scanning electron microscopy and fractal analysis 
Scanning electron microscopy demonstrated that dual anti-platelet therapy resulted 
in formation of clots with reduced fibrin density and increased fibrin strand diameter 
(Figure 5).  This reduction in clot density was consistent with the df measurements 
and projections of random fractal aggregates for the aspirin plus prasugrel and 
aspirin plus ticagrelor groups showing a reduction in the density of connectedness 
compared to that projected from blood collected under control conditions (Figure 6).     
 
Correlation analysis between fractal analysis and other parameters 
The relationships between pre and post treatment values of df and the haemostatic, 
haematological and platelet parameters are shown in Table 1. The only haemostatic 
or haematological parameter that showed a clear correlation with df was fibrinogen 
(0.376, p=0.04). Conversely, regarding the relationships between df and the various 
platelet activity tests significant correlations were found with AA (1mM) (0.332, 
p=0.006), ADP (5µM) (0.366, p=0.002), ADP (20µM) (0.369. 0.002), collagen 
(0.4µg/ml) (0.343, p=0.004) and TRAP-6 (25µM) (0.309, p=0.01).  
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Discussion 
Here using an advanced viscoelastic technique we have identified that platelets are 
potential regulators of clot structure under clinically relevant conditions. This and 
previous studies show that our technique could be applied to investigate the 
functional relationship between coagulation pathways, platelets, eventual clot quality 
and outcome. This is relevant as increased platelet reactivity represents an important 
and potentially modifiable risk factor for thrombosis 40; if reliably identified then it 
could be modified by individualised anti-platelet therapy regimes. A possible 
limitation of standard kinetic markers is their focus on individual components of 
platelet reactivity, coagulation or fibrinolysis alone which fails to distinguish abnormal 
clot architecture. 
 
Our study is the first to apply the measurement of df to quantify differences in 
structural organisation and mechanical properties of blood clots secondary to 
individual and combined anti-platelet therapy regimes. Analysis of pre-treatment 
blood indicated a clearly defined df value within a narrow range, representing a 
normal index of haemostasis where df = 1.72 (± 0.05). Further analysis of pre and 
post treatment df values demonstrated a clear correlation with fibrinogen (0.376, 
p=0.04) (Table 1).  
 
In control conditions we observed platelet reactivity responses within the normal 
ranges reported for healthy volunteers [11, 36, 37]. Following treatment with aspirin 
or prasugrel we noted powerful inhibition of platelet responses to AA or ADP 
respectively, in keeping with consensus statement indicators of effective therapy [11, 
37]. Aspirin monotherapy also inhibited platelet aggregations induced by low 
Page 15 of 38
URL: http://mc.manuscriptcentral.com/cpla E-mail: P.Harrison.1@bham.ac.uk
Platelets
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
16 
 
concentrations of ADP and collagen. ATP release, activation of GP IIb/IIIa receptors 
and p-selectin expression were not significantly affected. In accordance with these 
limited effects on platelet function, aspirin produced no significant change in clot 
structure as detected by df (1.71±0.01 to 1.69±0.01, p=0.41). The change in mean 
relative mass was also non-significant (-8±19% change, p=0.47). Prasugrel 
monotherapy substantially blunted platelet aggregation responses to all agonists 
tested apart from TRAP-6 and caused significant reductions in ATP release, p-
selectin expression and GP IIb/IIIa receptor activation. Platelet inhibition was 
associated with both a significant reduction in df (1.72±0.02 to 1.67±0.01, p =0.03) 
and a considerable change in the mean relative mass of incipient clots (-40±11% 
change, p=0.03) indicative of a substantial change in structure. 
  
Following our monotherapy studies, which indicated a strong association between 
platelet activity and clot architecture we then sought to characterise the influences of 
dual anti-platelet therapy. Administration of aspirin plus prasugrel or aspirin plus 
ticagrelor resulted in significant levels of platelet inhibition to all agonists, abolishing 
responses to weaker agonists tested. P-selectin expression was also significantly 
reduced in both groups. Again, significant platelet inhibition was coupled with a 
reduction in df: aspirin plus prasugrel (1.73±0.02 to 1.68±0.02, p=0.03) and aspirin 
plus ticagrelor (1.72±0.03 to 1.62±0.02, p=0.04). There were also significant 
reductions in mean relative mass both for aspirin plus prasugrel (-35±16% change, 
p=0.04) and for aspirin plus ticagrelor (-45±14% change, p=0.04).  
 
Overall the anti-platelet therapies had little effect on haematological and haemostatic 
parameters (Supplemental Tables 2,3,4,5 & 7) but the changes in Df did correlate 
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with changes in the platelet reactivity tests (see Table 1). Whilst as noted above, df 
correlates with fibrinogen concentration it is important to note that fibrinogen 
concentrations did not change between the pre- and post- measurements for any of 
the anti-platelet drugs tested (aspirin, prasugrel, aspirin plus prasugrel, and aspirin 
plus ticagrelor). This indicates that the magnitude of df is not solely dependent on the 
amount of fibrinogen present, but also how the processes through which fibrinogen 
forms a fibrin network dependent upon platelet reactivity.  
 
Overall our results clearly demonstrate that stronger inhibition of platelet function is 
associated with the formation of less dense clots comprised of a more open/porous 
network of fibrin strands. Where the inhibition of platelet function could affect other 
activities such as coagulation and thrombin activation which would the regulate fibrin 
strand formation.  It is important to recognise that df has a very narrow range and to 
appreciate the non-linear relationship between df and fibrin mass. Figure 6 helps in 
this regard by providing a visual projection of how relatively small changes in fractal 
dimension would underlie large changes in the mass of random fractal aggregates 
(RFA); notably the lowest fractal dimension has a lower frequency of high-density 
regions (i.e. the number of nearest neighbours is relatively low) consequently the 
projected form is relatively sparse and open which would equate to a mechanically 
weaker and more highly friable clot. On the contrary, the RFA with the highest df is 
relatively more compact, due to the larger number of high density regions within the 
structure. The density regions constrain the possible positional configurations of 
adjacent constituent particles, i.e. reducing on average the spacing between 
adjacent particles resulting in a relatively denser structure which would correspond to 
a mechanically stronger clot less susceptible to breakdown. This predicted link 
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between df and thrombus structure is confirmed by scanning electron micrographs 
(SEM), which demonstrate a more open clot structure following treatment with anti-
platelet therapies (Figure 5). These SEM images, in keeping with our previous 
studies highlight that incipient clot structure quantified by df acts as a template to 
predict the structure of the mature clot. Notably, the fibrin strands are much thicker in 
the post- as opposed to the pre-treatment images (df 1.67 versus df 1.63) and the 
number of small round particles, which represent platelets, is much reduced. This is 
in keeping with the association of thick fibrin strands with more porous clots and 
reduced platelet-fibrin interactions which we could expect following DAPT with 
aspirin plus ticagrelor in our healthy volunteer subject. 
 
Results from our studies using standard single and dual anti-platelet therapy 
demonstrate that it is activation of P2Y12 receptors that is the key driver of platelet 
interactions in clot formation, in keeping with the contribution of ADP but not TXA2 
receptors in the initiation of intravascular coagulation [38]. We did not observe a 
significant microstructural change in volunteers taking aspirin 75mg, in keeping with 
a minimal reduction in platelet reactivity. This contrasts with a recent study, where 
treatment with 300mg aspirin in patients with ischaemic stroke produced a significant 
reduction in df.[28] Aspirin primarily acts to inhibit platelet cyclo-oxygenase-1 
however, at higher doses it exerts other effects such as acetylation of fibrinogen, 
prothrombin and other coagulation factors [39] [40]. Therefore, we could anticipate to 
detect this direct role in clot modulation with higher doses of aspirin (300mg) but 
perhaps not at lower doses (75mg) and this difference was readily detectable by our 
global haemorheological marker of clot structure. It is also notable that addition of 
aspirin to prasugrel produced no further reduction in markers of clot density despite 
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additional inhibition of platelet thromboxane A2 pathways. As we have suggested 
previously this may indicate that in the presence of strong P2Y12 receptor blockade 
aspirin produces little or no additional therapeutic benefit [41, 42]. 
 
Our results are readily understandable as platelets are central to several key 
coagulation processes. Activated platelets expose phosphatidylserine to support the 
function of the prothrombinase complex greatly enhancing coagulation [43], interact 
with many coagulation factors [44, 45] and associate with tissue factor [46]. Platelets 
are instrumental in providing a surface for large scale thrombin production [47] and 
are involved in fibrin formation and organisation with activated GPIIb/IIIa receptors 
regulating clot retraction [48]. Previous studies have shown that platelets are 
important in fibrin fibre growth where the fibres originate from the platelet aggregates 
in clots formed in platelet-rich plasma [49]. This is an important consideration in 
understanding df as it is derived from a viscoelastic measurement of the incipient clot 
formation, where the fibrin network provides the dominant viscoelastic response [26].   
Dense regions of fibres would inevitably influence the viscoelastic properties and 
consequently the value of df.  Therefore, platelets as the promotors of fibrin fibre 
growth would contribute to an increase in elasticity and thus a corresponding 
increase in the df.  Consequently, in the presence of platelet inhibition and hence a 
reduction in the number, or absence, of platelet aggregates a lower value of df would 
be expected. In the present study comparison of responses in the absence and 
presence of different levels of platelet inhibition identifies a significant relationship 
between platelet function and the complex, highly disordered structure of incipient 
clots in whole unadulterated blood from healthy volunteers, echoing a previous 
report that altered clot structures are associated with aspirin treatment failure [50]. 
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As well as providing further mechanistic insight into the links between platelet 
reactivity and clot formation, our data indicates that the therapeutic benefits of anti-
platelet therapies are dependent upon their abilities to reduce thrombus density. 
Analysis of our SEM micrographs further confirms that these anti-thrombotic effects 
are partly attributable to the formation of thicker fibrin fibres, increased volume of 
pore spaces and an increased permeability of the clot’s fibrinolytic components. This 
deeper understanding of the role of platelets in thrombus formation could be useful in 
individual patients to determine the functional relationship between platelet reactivity, 
eventual clot quality and clinical outcome.  
 
Given the numerous mechanisms by which platelets and the coagulation system 
interact, a more comprehensive marker of coagulation, thrombosis and the response 
to therapeutic manipulation, could prove important in the prediction of 
thromboembolic complications. Our observations support that indices of fractal 
analysis are intricately linked and reflect clot structure and strength and are 
representative of the dynamic and interwoven properties of the fibrin clot and platelet 
reactivity. Importantly, this study has shown that df can quantify the effects of 
individual therapeutic interventions. The development of df as a point of care test to 
assess clot structure may have potential as a future tool in quantifying thrombotic 
risk, through identifying those patients who form abnormal clot structures that are 
associated with impaired clot lysis and increased potential to embolise. Exploited in 
this way, df could prove a rapid means of influencing clinical decisions in the 
management of bleeding and thrombotic risk, providing more insight into the 
combined effect of clotting factors and cellular components in terms of functional 
activity of the pathological clot and its properties. Rather than simply measuring 
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platelet reactivity a more thorough understanding of how the fibrin network is 
structurally organised could be more informative in determining the effects and 
outcomes of anti-platelet therapies in the clinical setting with the potential of 
individualising therapies. 
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Tables 
 
Table 1. Pearson correlation coefficients for df versus haemostatic, 
haematological and platelet parameters  
Parameter Correlation coefficient 
Fibrinogen   0.376 * 
PT -0.301 
APTT 0.154 
Platelets 0.171 
Haemoglobin 0.238 
Haematocrit 0.252 
AA (1 mM) 0.332* 
ADP (5 µM) 0.366* 
ADP (20 µM) 0.369* 
Collagen (0.4 µg/ml) 0.343* 
Collagen (4 µg/ml) 0.237 
U46619 (10 µM) 0.231 
TRAP-6 (25 µM) 0.309* 
P Selectin Exp. 0.079 
PAC-1 Binding 0.335 
ATP Release 0.286 
 
* = Significant result (p<0.05) 
PT indicates prothrombin time; APPT activated partial thromboplastin time; df fractal 
dimension 
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Figure Legends 
 
Figure 1. Effects of aspirin (75 mg) therapy on platelet reactivity. Bar graphs 
representing platelet responses before and after treatment measured by: A) standard 
light transmission aggregometry to AA (1 mM), ADP (5 and 20 µM), collagen (0.4 
and 4 µg/mL), U46619 (10 µM) and TRAP-6 amide (25 µM); B) P-selectin 
expression; C) PAC-1 binding and D) ATP release after collagen (4 µg/ml) 
stimulation. Data are presented as final aggregation (%, mean±SEM), ATP release 
(nmol, mean±SEM) or geometric mean fluorescence index (MFI) (units, 
mean±SEM). Significance is shown as * p<0.05 vs non-treated throughout. 
 
Figure 2. Effects of prasugrel (10 mg) therapy on platelet reactivity. Bar graphs 
representing platelet responses before and after treatment measured by: A) standard 
light transmission aggregometry to AA (1 mM), ADP (5 and 20 µM), collagen (0.4 
and 4 µg/mL), U46619 (10 µM) and TRAP-6 amide (25 µM); B) P-selectin 
expression; C) PAC-1 binding and D) ATP release after collagen (4 µg/ml) 
stimulation. Data are presented as final aggregation (%, mean±SEM), ATP release 
(nmol, mean±SEM) or geometric mean fluorescence index (MFI) (units, 
mean±SEM). Significance is shown as * p<0.05 vs non-treated throughout. 
Figure 3. Effect of dual antiplatelet therapy with aspirin (75mg) plus prasugrel 
(10 mg) on platelet reactivity. Bar graphs demonstrating platelet responses before 
and after treatment measured by: A) standard light transmission aggregometry to AA 
(1 mM), ADP (5 and 20 µM), collagen (0.4, and 4 µg/mL), TRAP-6 amide (25 µM) 
and U46619 (10 µM);  and B) TRAP-6 (25 µM) induced P-selectin expression.  Data 
are presented as final aggregation (%, mean±SEM) or geometric mean fluorescence 
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index (MFI) (units, mean±SEM). Significance is shown as * p<0.05 vs non-treated 
throughout. 
 
Figure 4. Effect of dual antiplatelet therapy with aspirin (75mg) plus ticagrelor 
(90 mg) on platelet reactivity. Bar graphs depicting platelet responses prior to and 
following treatment as measured by: A) standard light transmission aggregometry to 
AA (1 mM), ADP (5 and 20 µM), collagen (0.4, and 4 µg/mL), TRAP-6 amide (25 µM) 
and U46619 (10 µM); and B) TRAP-6 (25 µM) induced P-selectin expression. Data 
are presented as final aggregation (%, mean±SEM) or geometric mean fluorescence 
index (MFI) (units, mean±SEM). Significance is shown as * p<0.05 vs non-treated 
throughout. 
 
Figure 5. Effect of dual antiplatelet therapy with aspirin (75 mg) plus ticagrelor 
(90 mg) on clot structure. Corresponding SEM micrographs of clots formed in 
blood taken from one participant, before (panels (a) and (c); df 1.67) and after 
(panels (b) and (d); df 1.63) treatment with aspirin (75mg) plus ticagrelor (90 mg). 
Micrographs were captured at two different magnifications for the pre- and post-dual 
antiplatelet therapy with aspirin and ticagrelor. The magnifications chosen were 5K 
(panels (a) and (b)) and 10K (panels (c) and (d)).  Sections of the micrograph 
showing only the fibrin network were chosen to highlight the differences in the pre- 
and post- condition on clot microstructural development.  
 
Page 29 of 38
URL: http://mc.manuscriptcentral.com/cpla E-mail: P.Harrison.1@bham.ac.uk
Platelets
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
30 
 
Figure 6: Visualisation of the relationship between fractal dimension and 
mass. Figure (a) shows the variation of the mass of a random fractal aggregate 
(RFA) as a function of fractal dimension. The magnitude of the RFA is normalized to 
the mean healthy value, df = 1.72 (green circle). Additionally two further points are 
highlighted on Figure (a) showing the mass values of two RFA’s with df values of 
1.68 (red square) and  1.63 (black triangle). The red square being equivalent to the 
df found for the aspirin + prasugrel and the black triangle being equivalent to the 
aspirin + ticagrelor group. Figures (b), (c) and (d) are numerical realisations of RFAs 
corresponding to fractal dimensions of  (b)1.63 (aspirin + ticagrelor), (c) 1.68 (aspirin 
+ prasugrel) and (d) 1.72 (normal). Each numerical realisation of RFA is comprised 
of several constituent particles of unit diameter all of which are connected to at least 
one other particle. The colour index in the RFA realisations represents the local 
densities of constituent connected particles (green and red shades represent low 
and high density regions respectively). A RFA realisation containing many red areas 
denotes a more compact, densely connected structure than a RFA with 
predominately green areas. 
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Figure 1. Effects of aspirin (75 mg) therapy on platelet reactivity.  
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Figure 2. Effects of prasugrel (10 mg) therapy on platelet reactivity.  
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Figure 3. Effect of dual antiplatelet therapy with aspirin (75mg) plus prasugrel (10 mg) on platelet reactivity. 
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Figure 4. Effect of dual antiplatelet therapy with aspirin (75mg) plus ticagrelor (90 mg) on platelet reactivity. 
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Figure 5. Effect of dual antiplatelet therapy with aspirin (75 mg) plus ticagrelor (90 mg) on clot structure. 
Corresponding SEM micrographs of clots formed in blood taken from one participant, before (panels (a) and 
(c); df 1.67) and after (panels (b) and (d); df 1.63) treatment with aspirin (75mg) plus ticagrelor (90 mg). 
Micrographs were captured at two different magnifications for the pre- and post-dual antiplatelet therapy 
with aspirin and ticagrelor. The magnifications chosen were 5K (panels (a) and (b)) and 10K (panels (c) and 
(d)).  Sections of the micrograph showing only the fibrin network were chosen to highlight the differences in 
the pre- and post- condition on clot microstructural development.  
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Figure 6: Visualisation of the relationship between fractal dimension and mass. Figure (a) shows the 
variation of the mass of a random fractal aggregate (RFA) as a function of fractal dimension. The magnitude 
of the RFA is normalized to the mean healthy value, df = 1.72 (green circle). Additionally two further points 
are highlighted on Figure (a) showing the mass values of two RFA’s with df values of 1.68 (red square) 
and  1.63 (black triangle). The red square being equivalent to the df found for the aspirin + prasugrel and 
the black triangle being equivalent to the aspirin + ticagrelor group. Figures (b), (c) and (d) are numerical 
realisations of RFAs corresponding to fractal dimensions of  (b)1.63 (aspirin + ticagrelor), (c) 1.68 (aspirin + 
prasugrel) and (d) 1.72 (normal). Each numerical realisation of RFA is comprised of several constituent 
particles of unit diameter all of which are connected to at least one other particle. The colour index in the 
RFA realisations represents the local densities of constituent connected particles (green and red shades 
represent low and high density regions respectively). A RFA realisation containing many red areas denotes a 
more compact, densely connected structure than a RFA with predominately green areas.  
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Supplemental data 
 
Table 2. Haematological and haemostatic parameters pre and post aspirin therapy. 
 No treatment Aspirin 
Hb 15.1 ± 0.36 14.9 ± 0.31 
HCT 0.44 ± 0.01 0.43 ± 0.01 
Plt 210 ± 16.1 217 ± 13.5 
PT 10.6 ± 0.2 11 ± 0.22 
APPT 27.88 ± 0.92 28.63 ± 0.89 
APPTr 1.09 ± 0.03 1.1 ± 0.03 
INR 0.99 ± 0.02 1.03 ± 0.03 
Fibrinogen 1.98 ± 0.16 1.88 ± 0.15 
 
 
Table 3.  Haematological and haemostatic parameters pre and post prasugrel therapy. 
 No treatm nt Prasugrel 
Hb 14.9 ± 0.28 14.4 ± 0.25 
HCT 0.44 ± 0.01 0.42 ± 0.01 
Plt 237 ± 9.56 237 ± 11.6 
PT 10.6 ± 0.08 11 ± 0.15 
APPT 27.25 ± 0.75 27.50 ± 0.73 
APPTr 1.05 ± 0.03 1.05 ± 0.03 
INR 1.00 ± 0.00 1.01 ± 0.01 
Fibrinogen 2.04 ± 0.14 1.98 ± 0.13 
 
 
Table 4. Haematological and haemostatic parameters pre and post DAPT with aspirin 
and prasugrel therapy. 
 No treatment Aspirin + Prasugrel 
Hb 15.6 ± 0.34 15.5 ± 0.36 
HCT 0.47 ± 0.01 0.48 ± 0.01 
Plt 173 ± 25 175 ± 25.5 
PT 11.2 ± 0.23 11 ± 0.28 
APPT 29 ± 1.00 28 ± 0.9 
APPTr 1.11 ± 0.04 1.06 ± 0.04 
INR 1.09 ± 0.03 1.06 ± 0.03  
Fibrinogen 2.03 ± 0.07 2.16 ± 0.17 
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Table 5. Haematological and haemostatic parameters pre and post DAPT with aspirin 
and ticagrelor therapy. 
 No treatment Aspirin + Ticagrelor 
Hb 14.8 ± 0.41 14.7 ± 0.37 
HCT 0.42 ± 0.01 0.41 ± 0.01 
Plt 208 ± 7.2 218 ± 7.5 
PT 10.7 ± 0.14 10.7 ± 0.17 
APPT 28.0 ± 0.42 26.8 ± 0.55 
APPTr 1.09 ± 0.01 1.04 ± 0.02 
INR 1.07 ± 0.02 1.03 ± 0.02 
Fibrinogen 2.05 ± 0.23     2.10 ± 0.14 
 
Table 6. Gel time (TGP) rheological parameter pre and post aspirin, DAPT with aspirin 
and prasugrel therapy (A+P) & DAPT with aspirin and ticagrelor therapy (A+T). 
 Pre (sec) Post (sec) 
Aspirin 162 ± 41 174 ± 43 
Prasugrel 152 ± 64 166 ± 28 
A+P 193 ± 78 183 ± 81 
A+T 219 ± 100 201 ± 79 
 
Table 7. Fractal dimension (df) rheological parameter pre and post aspirin, DAPT with 
aspirin and prasugrel therapy (A+P) & DAPT with aspirin and ticagrelor therapy (A+T). 
 Pre (sec) Post (sec) 
Aspirin 1.71 ± 0.01 1.69 ± 0.01 
Prasugrel 1.72 ± 0.02 1.67 ± 0.01* (p=0.03) 
A+P 1.73 ± 0.02 1.68 ± 0.02* (p=0.03) 
A+T 1.72 ± 0.03 1.61 ± 0.02* (p=0.04) 
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